Transgelin/TAGLN/SM22 alpha Antibody - BSA Free

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody [NBP1-33003]

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody [NBP1-33003] - A. 30 ug Rat-2 whole cell lysate/extract 12 % SDS-PAGE Transgelin antibody dilution: 1:5000

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody [NBP1-33003]

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody [NBP1-33003] - Non-transfected (-) and transfected (+) HeLa whole cell extracts (15 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with Transgelin antibody.

Immunohistochemistry-Paraffin: Transgelin/TAGLN/SM22 alpha Antibody [NBP1-33003]

Immunohistochemistry-Paraffin: Transgelin/TAGLN/SM22 alpha Antibody [NBP1-33003] - Rat stomach. Transgelin antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody [NBP1-33003] -

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody [NBP1-33003] -Various whole cell extracts (30 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with Transgelin antibody diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301 was used to detect the primary antibody.

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody [NBP1-33003] -

Various whole cell extracts (30 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with Transgelin antibody (NBP1-33003) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody - BSA Free [NBP1-33003] -

MAP4K4 deficiency induces TGF beta /smad signaling and EndMT via activation of integrin beta 1. (a) HMVECs were transfected with MAP4K4 siRNA (100 nM) for 48 h. Next, the cells were treated with or without AcSDKP for 2 h. The p-smad3/smad3 pathway was analyzed by western blot. Densitometric analysis of the p-smad3/smad3 levels was performed, with n=3 for each group. (b) HMVECs were treated with MAP4K4 siRNA for 48 h with or without AcSDKP treatment. The VE-cadherin, CD31, FSP1, SM22 alpha and vimentin protein levels were analyzed by western blot. (c) HMVECs were transfected with MAP4K4 siRNA for 48 h in the presence or absence of TGF beta 2 with or without AcSDKP. The integrin beta 1 level was analyzed by western blot Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28771231), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody - BSA Free [NBP1-33003] -

AcSDKP suppresses TGF beta /smad signaling and EndMT through the FGFR1/FRS2 pathway. (a) HMVECs were treated with N-FGFR1 for 48 h, and the FGFR1, TGF beta R1 and TGF beta R2 protein levels were analyzed by western blot. (b) HMVECs were treated with TGF beta 2 in the presence or absence of N-FGFR1 for 15 min with or without AcSDKP preincubation. The p-smad3 and TGF beta R1 protein levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3 and TGF beta R1/ beta -actin levels (n=3) in each group was performed. (c) HMVECs were incubated with either N-FGFR1 in the presence or absence of TGF beta 2 for 48 h with or without preincubation with AcSDKP for 2 h or with N-FGFR1 in the presence or absence of TGF beta 2 for 48 h with or without 24 h of incubation with FGF2 (50 ng/ml). The CD31, SM22 alpha, FSP1 and alpha -SMA protein levels were analyzed by western blot. (d) HMVECs were transfected with FRS2 siRNA (100 nM) for 48 h with or without AcSDKP preincubation. The VE-cadherin, FSP1, vimentin, SM22 alpha and p-smad3 levels were analyzed by western blot. (e) HMVECs were treated with N-FGFR1 for 48 h or 15 min in the presence or absence of N-TGF beta (1, 2, 3) (1.0 μg/ml). The CD31, VE-cadherin, SM22 alpha, FSP1, TGF beta R1, TGF beta R2 and p-smad3 levels were analyzed by western blot Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28771231), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody - BSA Free [NBP1-33003] -

AcSDKP suppresses TGF beta /smad signaling and EndMT through the FGFR1/FRS2 pathway. (a) HMVECs were treated with N-FGFR1 for 48 h, and the FGFR1, TGF beta R1 and TGF beta R2 protein levels were analyzed by western blot. (b) HMVECs were treated with TGF beta 2 in the presence or absence of N-FGFR1 for 15 min with or without AcSDKP preincubation. The p-smad3 and TGF beta R1 protein levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3 and TGF beta R1/ beta -actin levels (n=3) in each group was performed. (c) HMVECs were incubated with either N-FGFR1 in the presence or absence of TGF beta 2 for 48 h with or without preincubation with AcSDKP for 2 h or with N-FGFR1 in the presence or absence of TGF beta 2 for 48 h with or without 24 h of incubation with FGF2 (50 ng/ml). The CD31, SM22 alpha, FSP1 and alpha -SMA protein levels were analyzed by western blot. (d) HMVECs were transfected with FRS2 siRNA (100 nM) for 48 h with or without AcSDKP preincubation. The VE-cadherin, FSP1, vimentin, SM22 alpha and p-smad3 levels were analyzed by western blot. (e) HMVECs were treated with N-FGFR1 for 48 h or 15 min in the presence or absence of N-TGF beta (1, 2, 3) (1.0 μg/ml). The CD31, VE-cadherin, SM22 alpha, FSP1, TGF beta R1, TGF beta R2 and p-smad3 levels were analyzed by western blot Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28771231), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody - BSA Free [NBP1-33003] -

AcSDKP suppresses TGF beta /smad signaling and EndMT through the FGFR1/FRS2 pathway. (a) HMVECs were treated with N-FGFR1 for 48 h, and the FGFR1, TGF beta R1 and TGF beta R2 protein levels were analyzed by western blot. (b) HMVECs were treated with TGF beta 2 in the presence or absence of N-FGFR1 for 15 min with or without AcSDKP preincubation. The p-smad3 and TGF beta R1 protein levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3 and TGF beta R1/ beta -actin levels (n=3) in each group was performed. (c) HMVECs were incubated with either N-FGFR1 in the presence or absence of TGF beta 2 for 48 h with or without preincubation with AcSDKP for 2 h or with N-FGFR1 in the presence or absence of TGF beta 2 for 48 h with or without 24 h of incubation with FGF2 (50 ng/ml). The CD31, SM22 alpha, FSP1 and alpha -SMA protein levels were analyzed by western blot. (d) HMVECs were transfected with FRS2 siRNA (100 nM) for 48 h with or without AcSDKP preincubation. The VE-cadherin, FSP1, vimentin, SM22 alpha and p-smad3 levels were analyzed by western blot. (e) HMVECs were treated with N-FGFR1 for 48 h or 15 min in the presence or absence of N-TGF beta (1, 2, 3) (1.0 μg/ml). The CD31, VE-cadherin, SM22 alpha, FSP1, TGF beta R1, TGF beta R2 and p-smad3 levels were analyzed by western blot Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28771231), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Transgelin/TAGLN/SM22 alpha Antibody - BSA Free [NBP1-33003] -

KLB deficiency led to EndMT in HMVECs. (A) Subconfluent HMVECs were transfected with KLB siRNA or control siRNA. Six hours later, the medium was replaced with an experimental medium, followed by N‐FGFR1 (1.5 mg·mL−1) treatment. At 48 h, the cells were harvested for western blot analysis. The results are from three repeated experiments. (B) The same treated HMVECs (as in A) cultured on 8‐well culture slides were subjected to immunofluorescence staining with an anti‐ alpha ‐SMA antibody and DAPI (scale bar, 100 μm). Six different fields were observed for each slide. (C) HMVECs with or without preincubation with AcSDKP (100 nm) for 2 h were transfected with KLB siRNA or control siRNA for 48 h. The expression of EndMT markers, including VE‐cadherin, alpha ‐SMA, vimentin, and SM22 alpha, was assessed by western blotting and quantified (D) by imagej software (GE Healthcare Life Sciences, Uppsala, Sweden). The data represent mean +/- SD and are representative of three independent experiments. One‐way ANOVA with Tukey's multiple comparisons test was used for statistical analysis. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/30972974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.